Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
EBioMedicine ; 50: 274-289, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31787569

ABSTRACT

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons (MNs). It was shown that human astrocytes with mutations in genes associated with ALS, like C9orf72 (C9) or SOD1, reduce survival of MNs. Astrocyte toxicity may be related to their dysfunction or the release of neurotoxic factors. METHODS: We used human induced pluripotent stem cell-derived astrocytes from ALS patients carrying C9orf72 mutations and non-affected donors. We utilized these cells to investigate astrocytic induced neuronal toxicity, changes in astrocyte transcription profile as well as changes in secretome profiles. FINDINGS: We report that C9-mutated astrocytes are toxic to MNs via soluble factors. The toxic effects of astrocytes are positively correlated with the length of astrocyte propagation in culture, consistent with the age-related nature of ALS. We show that C9-mutated astrocytes downregulate the secretion of several antioxidant proteins. In line with these findings, we show increased astrocytic oxidative stress and senescence. Importantly, media conditioned by C9-astrocytes increased oxidative stress in wild type MNs. INTERPRETATION: Our results suggest that dysfunction of C9-astrocytes leads to oxidative stress of themselves and MNs, which probably contributes to neurodegeneration. Our findings suggest that therapeutic strategies in familial ALS must not only target MNs but also focus on astrocytes to abrogate nervous system injury.


Subject(s)
Amyotrophic Lateral Sclerosis/etiology , Amyotrophic Lateral Sclerosis/metabolism , Astrocytes/cytology , Astrocytes/metabolism , C9orf72 Protein/genetics , Induced Pluripotent Stem Cells/cytology , Mutation , Oxidative Stress , Amyotrophic Lateral Sclerosis/physiopathology , Animals , Biomarkers , Cells, Cultured , Cellular Reprogramming , Cellular Senescence/genetics , Cerebral Cortex/cytology , Cerebral Cortex/metabolism , Disease Models, Animal , Gene Expression Profiling , Glutamic Acid/metabolism , Humans , Mice , Motor Neurons/metabolism , Proteomics/methods , Reactive Oxygen Species/metabolism
2.
Cell Death Dis ; 9(3): 256, 2018 02 15.
Article in English | MEDLINE | ID: mdl-29449528

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by cell death of upper and lower motor neurons (MNs). The cause of MN cell loss is not completely understood but involves both cell autonomous and non-cell autonomous mechanisms. Numerous molecules have been implicated to be involved in the death of MNs. One such candidate is semaphorin 3A (Sema3A). In ALS patients, Sema3A was shown to be significantly upregulated in the motor cortex and downregulated in the spinal cord. In the mouse, Sema3A was shown to be an axon repellent molecule for MNs. Sema3A could also induce death of different neuronal types that are also repelled by it, including sensory, sympathetic, retinal, and cortical neurons. In contrast, astrocyte-specific knockout of Sema3A results in motor neuron cell death, consistent with the idea that Sema3A is a survival factor for mouse motor neurons. Here, we tested the response of human cortical neurons and spinal cord MNs to Sema3A. We found that Sema3A enhances the survival of spinal cord MNs. In contrast, Sema3A reduces the survival of cortical neurons. Thus, both upregulation of Sema3A in the cortex, or downregulation in the spinal cord of ALS patients is likely to directly contribute to MNs cell loss in ALS patients.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Cerebral Cortex/drug effects , Motor Neurons/drug effects , Semaphorin-3A/pharmacology , Spinal Nerves/drug effects , Amyotrophic Lateral Sclerosis/metabolism , Cell Death , Cell Line , Cell Survival , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Humans , Motor Neurons/metabolism , Motor Neurons/pathology , Neuropilins/metabolism , Semaphorin-3A/metabolism , Spinal Nerves/metabolism , Spinal Nerves/pathology
3.
PLoS One ; 10(10): e0138807, 2015.
Article in English | MEDLINE | ID: mdl-26437462

ABSTRACT

A splicing mutation in the IKBKAP gene causes Familial Dysautonomia (FD), affecting the IKAP protein expression levels and proper development and function of the peripheral nervous system (PNS). Here we found new molecular insights for the IKAP role and the impact of the FD mutation in the human PNS lineage by using a novel and unique human embryonic stem cell (hESC) line homozygous to the FD mutation originated by pre implantation genetic diagnosis (PGD) analysis. We found that IKBKAP downregulation during PNS differentiation affects normal migration in FD-hESC derived neural crest cells (NCC) while at later stages the PNS neurons show reduced intracellular colocalization between vesicular proteins and IKAP. Comparative wide transcriptome analysis of FD and WT hESC-derived neurons together with the analysis of human brains from FD and WT 12 weeks old embryos and experimental validation of the results confirmed that synaptic vesicular and neuronal transport genes are directly or indirectly affected by IKBKAP downregulation in FD neurons. Moreover we show that kinetin (a drug that corrects IKBKAP alternative splicing) promotes the recovery of IKAP expression and these IKAP functional associated genes identified in the study. Altogether, these results support the view that IKAP might be a vesicular like protein that might be involved in neuronal transport in hESC derived PNS neurons. This function seems to be mostly affected in FD-hESC derived PNS neurons probably reflecting some PNS neuronal dysfunction observed in FD.


Subject(s)
Carrier Proteins/metabolism , Down-Regulation , Dysautonomia, Familial/genetics , Human Embryonic Stem Cells/pathology , Neurons/metabolism , Peripheral Nervous System/pathology , Synaptic Vesicles/metabolism , Biological Transport/drug effects , Biological Transport/genetics , Carrier Proteins/genetics , Cell Differentiation/drug effects , Down-Regulation/drug effects , Dysautonomia, Familial/metabolism , Dysautonomia, Familial/pathology , Fetus , Human Embryonic Stem Cells/drug effects , Humans , Kinetin/pharmacology , Male , Mutation , Neural Crest/drug effects , Neural Crest/pathology , Neurons/drug effects , Peripheral Nervous System/drug effects , Phenotype , Synaptic Vesicles/drug effects , Transcriptional Elongation Factors
4.
Eur J Cell Biol ; 94(10): 453-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26111659

ABSTRACT

The biological activity of a recombinant protein is routinely measured using a bioassay such as an enzyme assay. However, many proteins have no enzymatic activity and in many cases it is difficult to devise a simple and reliable approach to test their activity. Semaphorins, Ephrins, Slits, Netrins or amylin-assisted proteins have numerous activities affecting many systems and cell types in the human body. Most of them are also able to induce rapid cytoskeleton changes at least in some cell types. We assumed therefore, that such proteins might be tested based on their ability to modulate the cytoskeleton. Here we tested a number of semaphorins in an impedance based label-free platform that allows for dynamic monitoring of subtle morphological and adhesive changes. This system has proved to be a very fast, sensitive and effective way to monitor and determine the activity of such proteins. Furthermore we showed that it is possible to customize a cell-protein system by transfecting the cells with specific receptors and test the cell response following the addition of the recombinant ligand protein. Since other protein families such as Ephrins and Netrins can also influence the cytoskeleton of some cells, this approach may be applicable to a large number of proteins.


Subject(s)
Biological Assay/methods , Recombinant Proteins/analysis , Semaphorins/analysis , Animals , Cytoskeleton , Electric Impedance , Humans , Ligands , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Receptors, Cell Surface/analysis , Receptors, Cell Surface/genetics , Receptors, Cell Surface/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Semaphorins/genetics , Semaphorins/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...